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A 62-year-old woman diagnosed with gallbladder cancer exhibiting broad liver invasion and metastasis to
Couinaud’s hepatic segments 4 and 8 (S4 and S8) consulted her regular doctor. Owing to the presence of liver
metastases, she received treatment with gemcitabine plus S-1. After four cycles of chemotherapy, the size of the
main lesion dramatically decreased and the two liver metastases disappeared. After six cycles of chemotherapy,
the patient was referred to our hospital for surgical treatment. Upon admission, there was no evidence of any
distant metastasis, based on a detailed radiological examination. Therefore, we performed cholecystectomy and
central bisegmentectomy of the liver after obtaining the patient’s informed consent. Pathological examination
demonstrated viable cancer cells with granuloma formation and calcification in the gallbladder, as well as
regenerative changes without viable cancer cells in S4 and S8 of the liver. Gemcitabine plus S-1 was again
administered as postoperative adjuvant chemotherapy. One and a half years after the surgery, there were no
signs of recurrence. In patients selected according to their response to chemotherapy, surgical treatment might
therefore be effective against gallbladder cancer with metastasis.
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Although complete surgical resection is the only curative
modality for biliary tract cancer, even patients who re-
ceive curative resection frequently develop recurrence of
the disease [1,2]. Moreover, no standard chemotherapeu-
tic regimen for advanced biliary tract cancer has been
established to date. Recently, combined chemotherapeu-
tic regimens based on gemcitabine, such as gemcitabine
plus cisplatin and gemcitabine plus S-1, have become
available for patients with unresectable biliary tract can-
cer [3]. However, the response rates to these regimens
range from only 15% to 37%, and the overall survival
time is limited to 4.7 to 15.4 months [4]. By contrast,
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sectable gallbladder cancer have been reported [5-11]. In
this report, we describe our successful treatment of a pa-
tient with gallbladder cancer with direct liver infiltration
and two hepatic metastases using gemcitabine plus S-1
followed by complete surgical resection.
Case presentation
A 62-year-old woman underwent a periodic computed
tomography (CT) examination for hepatitis B at another
hospital, where she was diagnosed with significantly ad-
vanced gallbladder cancer. Her weight was 50.5 kg and
her height was 153 cm, and a physical examination re-
vealed no abnormalities. Laboratory tests showed slight
elevation of the carbohydrate antigen (CA) 19-9 level at
57 U/ml; however, most of the other results were nor-
mal. Enhanced abdominal CT scans obtained on the firstal Ltd. This is an Open Access article distributed under the terms of the Creative
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bladder that had invaded the anterior and medial seg-
ments of the liver. In addition, two annular enhanced
masses in Couinaud’s hepatic segments 4 and 8 (S4 and
S8; Figure 1a) were observed on CT examination. The
patient was therefore diagnosed as having advanced
gallbladder cancer with direct liver invasion and hema-
togenous metastasis to the liver, T4 N0 M1; stage IVb
according to the American Joint Committee on Cancer
tumor-node-metastasis (TNM) classification. The dis-
ease was judged to be inoperable, owing to the liver
metastasis.
After obtaining the patient’s informed consent, chemo-
therapy with gemcitabine plus S-1 was started at a dose
of 1,200 mg of gemcitabine once a week for three weeks
and 100 mg of S-1 every day for three weeks, followed
by one week of rest. Because the patient experienced
grade 3 appetite loss, according to the National Cancer
Institute common toxicity criteria, the frequency of S-1
administration was reduced to every other day, starting
with the second cycle of chemotherapy. This change
allowed the patient to continue to receive the treatment
as an outpatient. The serum CA19-9 level gradually de-
creased, and a follow-up CT scan performed after four
cycles showed the main lesion to have dramatically re-
duced in size, while the two liver metastases had com-
pletely disappeared (Figure 1b). At that time, we were
consulted regarding the feasibility of surgical treatment.
We therefore recommended an additional two cycles ofFigure 1 Changes in CT images of the gallbladder cancer and liver m
of chemotherapy.chemotherapy, hoping to obtain a further effect and con-
firm the absence of distant metastasis.
After the two additional cycles, a CT scan showed that
the tumor had further shrunk in size and was detected as
only a slightly contrasted lesion in the liver bed. The
serum CA19-9 level was 13 U/ml at that time. 18 F
fluorodeoxyglucose-positron emission tomography (FDG-
PET) showed no uptake of FDG in the main lesion or evi-
dence of distant organ metastasis.
One month after the final cycle of chemotherapy, we
performed cholecystectomy and central bisegmentect-
omy of the liver with D2 lymph node dissection, which
confirmed the absence of both peritoneal dissemination
and liver metastasis, based on intraoperative macro-
scopic and ultrasound findings. Pathological examination
demonstrated viable cancer cells (moderately differenti-
ated adenocarcinoma) with granuloma formation and
calcification on the free peritoneal side of the gallblad-
der. The cancer cells were found to have spread widely
in the mucosal layer of the gallbladder, although no dir-
ect invasion to the liver was observed. Clusters of viable
cancer cells were detected in the liver bed apart from
the main lesion, diagnosed as liver metastases. In
addition, three lymph node metastases were noted on
the posterior surface of the pancreatic head. The areas
of induration in the S8 segment showed microscopic re-
generative changes without viable cancer cells; these
findings were histologically compatible with a chemo-
therapeutic complete response (Figures 2 and 3).etastases: (a) before chemotherapy; (b) after four cycles
Figure 2 Macroscopic findings. Induration of the gallbladder was noted, with solid white lesions in the liver bed.
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course. The administration of gemcitabine plus S-1 was
restarted as adjuvant chemotherapy and six cycles of the
treatment were performed. One and a half years have
passed since the operation, with no signs of recurrent
disease.
Discussion
Owing to its anatomical characteristics, gallbladder can-
cer tends to be diagnosed at an advanced stage, resulting
in a poor prognosis. Although only complete surgical re-
section offers the opportunity for a cure, approximately
70% of patients are ineligible for surgery [2]. Moreover,
individuals who do undergo surgical resection often
eventually develop recurrence of the disease. Most
patients with unresectable or recurrent disease receive
palliative chemotherapy, to prolong their survival and
relieve symptoms.Figure 3 Microscopic findings. Viable cancer cells with granuloma forma
regenerative changes without viable cancer cells were observed in the liveIn 2009, the ABC-02 trial demonstrated the superiority
of the combination of gemcitabine and cisplatin in com-
parison with gemcitabine alone [12]. In particular, the
authors found that the combination regimen signifi-
cantly prolonged median survival time. In addition, the
efficacy of combination chemotherapy using gemcitabine
plus S-1 has been evaluated in clinical studies. Three re-
cent phase II studies [4,13,14] have established the effi-
cacy of this regimen for unresectable biliary tract cancer,
with an overall survival of 11.6 to 12.7 months, a one-
year survival rate of 44% to 52%, and a clinical response
rate of 32% to 40%. Based on these results, a large ran-
domized phase III study is now planned, to confirm the
non-inferiority of gemcitabine plus S-1 combination
therapy using a three-week regimen of gemcitabine plus
cisplatin combination therapy in Japan [3]. Although the
results of this phase III study have not yet been pub-
lished, we selected gemcitabine plus S-1 combinationtion and calcification were present in the gallbladder, while
r (S4 and S8). (a) H & E staining, ×40; (b) H & E staining, ×100.
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expectation of its efficacy.
We found that the patient’s two hepatic metastases
disappeared after four cycles of chemotherapy after
modifying the regimen, owing to grade 3 appetite loss.
However, we recommended that the patient receive an-
other two cycles of chemotherapy because we hoped for
a further effect and wished to confirm the long-term ab-
sence of distant metastasis. To date, there have been no
reports regarding the timing of surgery in such cases.
To our knowledge, only eight cases of initially un-
resectable advanced gallbladder cancer treated with
chemotherapy followed by curative surgery have been
reported [5-11]. The chemotherapy regimen included
gemcitabine alone in two cases, S-1 alone in two cases,
gemcitabine plus cisplatin in two cases, and gemcitabine
plus S-1 in two cases. The duration of treatment differed
in each patient.
With regard to surgical results, one patient died from
another disease without progression of gallbladder can-
cer two months after surgery [5], while the remaining
seven patients were each alive without recurrent disease
at 10 to 31 months after surgery. The survival data for
the patients who underwent resection after chemother-
apy appeared to be better than those of the patients with
unresectable biliary tract cancer [3]. Moreover, the ef-
fects of second-line chemotherapy for biliary tract can-
cer are unclear [3,15-24]. The development of effective
chemotherapy might allow patients with initially unre-
sectable gallbladder cancer to undergo curative surgery.
Surgical treatment should therefore be carefully timed to
avoid missing an opportunity for resection in such pa-
tients. However, determining the appropriate timing for
surgery is difficult and the decision must be made on a
case-by-case basis, as surgical methods differ according
to the location of the tumor and range of tumor
invasion.
In previous reports, the duration of chemotherapy
prior to surgery ranged from one to 16 cycles [5-11].
Although surgical strategies (resection of the gallblad-
der bed, bile duct, and liver, where metastatic disease is
originally present before chemotherapy, with or with-
out aggressive lymphadenectomy) for such patients
remain controversial, major hepatic resection and re-
construction of the bile duct are often required. There-
fore, the indications for and timing of surgery should
be carefully determined according to the general condi-
tion of the patient. There is no consensus regarding the
optimal postoperative adjuvant chemotherapy. We se-
lected gemcitabine plus S-1, since the efficacy of this
regimen was confirmed before surgery, performing six
cycles of the treatment. However, further research re-
garding the advantages of postoperative therapy is
needed.Conclusion
In this case, although the patient was diagnosed with
advanced gallbladder cancer with liver metastasis and
was not initially considered to be a candidate for surgical
resection, gemcitabine plus S-1 chemotherapy was ex-
tremely effective and radical surgery was ultimately per-
formed. One and a half years after the operation, there
are no signs of recurrence. Although the best strategy
for treating advanced gallbladder cancer has not been
established, surgical treatment might be effective against
gallbladder cancer with metastasis in patients selected
according to their response to chemotherapy.
Consent
Written informed consent was obtained from the patient
for the publication of this case report and any accom-
panying images. A copy of the written consent form is
available for review from the editor-in-chief of this
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